Eli Lilly Says Orforglipron Helps Maintain Weight Loss After Switching From Injectable Incretins to Oral GLP-1 Therapy in Phase 3 Trial

MT Newswires Live12-18 21:02

Eli Lilly (LLY) said Thursday its investigational oral GLP-1 drug orforglipron met primary and secondary endpoints in a phase 3 trial evaluating weight maintenance in adults with obesity who switched from injectable incretin.

Participants who switched from Wegovy to orforglipron maintained their previous weight loss, with an average difference of 0.9 kg at 52 weeks, while those switching from Zepbound maintained weight loss with an average difference of 5 kg, Eli Lilly said.

The company said the trial met its primary endpoint of superior percent maintenance of body weight reduction compared to placebo.

Eli Lilly said the safety and tolerability of orforglipron was consistent with previous phase 3 studies.

The company said it has submitted a new drug application for orforglipron to the US Food and Drug Administration for the treatment of adults with obesity or overweight.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment